File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: Enhanced HIV-1 Gag-specific immunity induced by a sPD-1-based vaccine directed to dendritic cells
Title | Enhanced HIV-1 Gag-specific immunity induced by a sPD-1-based vaccine directed to dendritic cells |
---|---|
Authors | |
Keywords | Medical sciences Allergology and immunology |
Issue Date | 2011 |
Publisher | American Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org |
Citation | The 98th Annual Meeting of the America Association of Immunologists (AAI 2011), San Francisco, CA., 13-17 May 2011. In Journal of Immunology, 2011, v. 186 suppl. 1, abstract no. 53.23 How to Cite? |
Abstract | HIV/AIDS is a serious disease worldwide. The development of a safe, effective and affordable HIV-1 vaccine remains the ultimate solution. This study is based on the discovery of a negative immune regulatory system, the PD-1/PD-L pathway, which exists on both human and other animals. The PD-1 ligands (PD-L1 and PD-L2) are expressed on DCs. So we hypothesize to utilize the soluble PD-1 parts to intervene in the negative signal transmission of the PD-1 pathway and to target the antigen to DCs as a mean to indentify vaccine strategy to enhance the virus specific immune responses. Here we constructed the novel vaccine and controls by inserting soluble PD-1 gene and/or HIV-1 p24 gene into the pVAX1 vector with fusing of rabbit Fc fragment named mspd1-p24-fc, and controls named mspd1-IgVΔ-p24-fc and p24-fc. When compared with control vaccines, we discovered that mspd1-p24fc can significantly enhance HIV-1 Gag-specific immune responses by measuring the number of IFN-γ expressed CD4 and CD8 T cells using Elispot assays and CD8 T cell tetramer staining. Furthermore, the mspd1-p24-fc can significantly enhance humoral immune responses by anti-Gag antibody titer analysis. Importantly, this novel vaccine protects mice against recombinant vaccinia virus-gagpol challenges. This novel vaccine design may be used as DNA vaccine model against other infectious disease and cancer which need eliciting significant antigen specific humoral and cellular immune responses. |
Persistent Identifier | http://hdl.handle.net/10722/137934 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 1.558 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, J | en_US |
dc.contributor.author | Wang, H | en_US |
dc.contributor.author | Tan, Z | en_US |
dc.contributor.author | Du, Y | en_US |
dc.contributor.author | Chen, Z | en_US |
dc.date.accessioned | 2011-08-26T14:37:16Z | - |
dc.date.available | 2011-08-26T14:37:16Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | The 98th Annual Meeting of the America Association of Immunologists (AAI 2011), San Francisco, CA., 13-17 May 2011. In Journal of Immunology, 2011, v. 186 suppl. 1, abstract no. 53.23 | en_US |
dc.identifier.issn | 0022-1767 | - |
dc.identifier.uri | http://hdl.handle.net/10722/137934 | - |
dc.description.abstract | HIV/AIDS is a serious disease worldwide. The development of a safe, effective and affordable HIV-1 vaccine remains the ultimate solution. This study is based on the discovery of a negative immune regulatory system, the PD-1/PD-L pathway, which exists on both human and other animals. The PD-1 ligands (PD-L1 and PD-L2) are expressed on DCs. So we hypothesize to utilize the soluble PD-1 parts to intervene in the negative signal transmission of the PD-1 pathway and to target the antigen to DCs as a mean to indentify vaccine strategy to enhance the virus specific immune responses. Here we constructed the novel vaccine and controls by inserting soluble PD-1 gene and/or HIV-1 p24 gene into the pVAX1 vector with fusing of rabbit Fc fragment named mspd1-p24-fc, and controls named mspd1-IgVΔ-p24-fc and p24-fc. When compared with control vaccines, we discovered that mspd1-p24fc can significantly enhance HIV-1 Gag-specific immune responses by measuring the number of IFN-γ expressed CD4 and CD8 T cells using Elispot assays and CD8 T cell tetramer staining. Furthermore, the mspd1-p24-fc can significantly enhance humoral immune responses by anti-Gag antibody titer analysis. Importantly, this novel vaccine protects mice against recombinant vaccinia virus-gagpol challenges. This novel vaccine design may be used as DNA vaccine model against other infectious disease and cancer which need eliciting significant antigen specific humoral and cellular immune responses. | - |
dc.language | eng | en_US |
dc.publisher | American Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org | - |
dc.relation.ispartof | Journal of Immunology | en_US |
dc.subject | Medical sciences | - |
dc.subject | Allergology and immunology | - |
dc.title | Enhanced HIV-1 Gag-specific immunity induced by a sPD-1-based vaccine directed to dendritic cells | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Zhou, J: jingying@hku.hk | en_US |
dc.identifier.email | Wang, H: hbwang@hkucc.hku.hk | en_US |
dc.identifier.email | Tan, Z: zhiwutan@hku.hk | en_US |
dc.identifier.email | Du, Y: biodu@hku.hk | en_US |
dc.identifier.email | Chen, Z: zchenai@hku.hk | - |
dc.identifier.authority | Chen, Z=rp00243 | en_US |
dc.identifier.hkuros | 190683 | en_US |
dc.identifier.volume | 186 | - |
dc.identifier.issue | suppl. 1 | - |
dc.identifier.spage | abstract no. 53.23 | - |
dc.identifier.epage | abstract no. 53.23 | - |
dc.identifier.isi | WOS:000209751701063 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0022-1767 | - |